A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

Fifth Medical Center of PLA General Hospital, Beijing

Beijing Cancer Hospital, Beijing

Beijing Chest Hospital, Capital Medical University, Beijing

The first hospital of jilin university, Changchun

Jilin Provincial Cancer Hospital, Changchun

Harbin Medical University Cancer Hospital, Harbin

Shanghai Chest Hospital, Shanghai

Fudan University Shanghai Cancer Center, Shanghai

Zhongshan Hospital, Fudan University, Shanghai

Gaoxin Hospital of The First Affilated Hospital of Anhui Medical University, Hefei

The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang

The Second Affiliated Hospital of Zhejiang University College of Medicine, Hangzhou

Sir Run Run Shaw Hospital of College of Medicine of Zhejiang University, Center for Oncology, Hangzhou

Zhejiang Cancer Hospital, Hangzhou

Fujian Province Oncology Hospital, Fuzhou

Hunan Provincial Tumor Hospital/Division of Oncology, Changsha

Guangdong Provincial People's Hospital, Guangzhou

Sichuan Province Cancer Hospital/Department of Pulmonary Tumor, Chengdu

West China Hospital, Sichuan University, Cancer center, Chengdu

Tangdu Hospital of Fourth Military Medical University, Xi’an

General Hospital of Eastern Theater Command, Nanjing, Jiangsu